• Beta Bionics closed an underwritten public offering raising USD 172.5 million in gross proceeds, before fees and expenses.
• Deal included 7,652,175 common shares priced at USD 17.25, pre-funded warrants for 1,043,484 shares priced at USD 17.2499.
• Underwriters exercised their option in full for 1,304,348 additional common shares.
• Net proceeds earmarked for general corporate purposes, including Mint commercialization, manufacturing expansion, R&D, clinical development, product enhancements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609171605PRIMZONEFULLFEED9829130) on September 17, 2026, and is solely responsible for the information contained therein.